Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Philip S. J. Weston 1†, Teresa Poole 1,2†, Antoinette O’Connor 1†, Amanda Heslegrave 3, Natalie S. Ryan 1, Yuying Liang 1, Ronald Druyeh 1, Simon Mead 4, Kaj Blennow 5, Jonathan M. Schott 1, Chris Frost 1,2, Henrik Zetterberg 3,5 and Nick C. Fox 1,3

Abstract

**Background:** To investigate how serum neurofilament light (NFL) concentration changes through the course of disease in familial Alzheimer’s disease (FAD) and to assess when NFL concentration first increases.

**Methods:** NFL was measured using an ultrasensitive immunoassay in 117 serum samples from 61 individuals from families with *PSEN1* or *APP* mutations in a longitudinal study (mean ± SD = 1.9 ± 1.1 visits/patient; inter-visit interval = 1.8 ± 1.1 years). The relationship between NFL concentration and estimated years to/from symptom onset (EYO) was modelled using linear regression, including all time points and robust standard errors to allow for repeated measurements, adjusting for age at visit and sex. Also, for the 27 participants who became symptomatic (during or before the study), NFL concentration was also modelled against known actual years to/from onset (AYO).

**Results:** There were 15 non-carriers and 46 mutation carriers (21 symptomatic; 25 presymptomatic). NFL concentration was increased (*p* = 0.045) in mutation carriers compared with non-carriers 15 years prior to expected symptom onset, increasing progressively thereafter. There was a significant inter- and intra-individual variability in the longitudinal pattern of change. Modelling NFL for the 27 mutation carriers with known AYO also showed a progressive increase over time.

**Conclusions:** There is evidence that serum NFL is increased more than a decade before the onset of clinical symptoms in FAD and rises thereafter. While there is variability in change over time, both within and between individuals, and more work is needed to understand the sources of this variability, serum NFL remains a promising, accessible biomarker of early neurodegeneration in presymptomatic Alzheimer’s disease.

**Keywords:** Search terms, [26] Alzheimer’s disease, [91] autosomal dominant, [111] neurofilament light, [111] blood, [111] longitudinal

Background

Biomarkers sensitive to early neurodegeneration in Alzheimer’s disease (AD) can facilitate early diagnosis, monitor disease progression, and support trials of potential disease-modifying therapies. A blood-based biomarker would be less invasive and likely cheaper than currently available imaging and cerebrospinal fluid measures. We previously reported that the concentration of serum neurofilament light (NFL) in autosomal dominant familial Alzheimer’s disease (FAD) mutation carriers was increased prior to the onset of clinical symptoms [1]. Serum NFL has also been shown to be closely associated with validated imaging and cognitive measures of early neurodegeneration [1, 2].

However, it remains uncertain when in relation to symptom onset, serum NFL first increases. Also, while clinically important phenotypic differences have been found within the spectrum of FAD, particularly between amyloid precursor protein (*APP*) and presenilin 1...
(PSEN1) mutation carriers, and within the PSEN1 gene between mutations located pre and post-codon 200 [3], it is unknown whether this heterogeneity translates to differences in NFL concentration.

We therefore carried out a longitudinal study, with an increased sample size, of serum NFL in FAD mutation carriers and mutation-negative relatives.

Methods
Participants

We recruited 61 participants from 30 FAD families to a longitudinal study of FAD at the Dementia Research Centre, University College London, between April 2010 and February 2018. Eligibility was either (i) clinical diagnosis of FAD or (ii) an FAD-affected parent. Twenty-one participants were symptomatic, with pathogenic mutations in the PSEN1 or APP genes; 40 were asymptomatic but at 50% risk of an inherited mutation and thereby of developing symptoms at a similar age to their parent.

Genetic test data on the presence or absence of a mutation in ‘at-risk’ participants were provided only to study statisticians. Estimated years to/from symptom onset (EYO) were calculated by subtracting parental age of onset of progressive cognitive symptoms from the participant’s current age. At each study visit, procedures undertaken included blood sampling, a semi-structured health questionnaire (including exclusion of recent head injury), neurological examination, and the clinical dementia rating scale.

In total, 117 serum samples were obtained and one third of participants (20/61) had three or more time points (mean ± SD per participant 1.92 ± 1.08). The mean ± SD inter-visit interval was 1.75 ± 1.09 years. An ultrasensitive immunoassay on the Simoa platform measured serum NFL, using a methodology described previously [4]. All samples were processed according to the same standardised operating procedure and measured as duplicates. Samples from all time points were also processed concurrently using the same kit and batch of reagents to maximise consistency of analyses. Coefficients of variation (CVs) for duplicate concentrations of subject samples and quality control (QC) samples were < 15%.

Following genetic testing, we found that there were a total of 46 mutation carriers (21 symptomatic and 25 presymptomatic) and 15 non-carriers in the study. The total number of serum samples from each group was 29 from the symptomatic mutation carriers, 54 from the presymptomatic carriers, and 36 from the non-carriers.

Statistical analysis

Summary baseline descriptive data were calculated for symptomatic mutation carriers, presymptomatic mutation carriers, and non-carriers, and observed NFL concentrations plotted for carriers and non-carriers. For several participants, there were large within-person changes in NFL concentrations over relatively short time intervals. This meant that although we had longitudinal data, we have not analysed it in a way that explicitly models longitudinal change within subjects because the large within-person variability in observed rates of change created convergence problems when we tried to fit a mixed effects model. Instead, a linear regression model was used, including all time points and robust (Huber-White) standard errors that allowed for repeated measurements within individuals [5, 6]. The dependent variable (NFL) was log-transformed, and the relationship with EYO was modelled using genetic mutation status and linear, quadratic and cubic terms for EYO, plus their interactions with mutation status, as predictor variables, adjusting for age at visit and sex. The estimated geometric mean longitudinal NFL concentration profiles for the two groups (and 95% confidence intervals) were plotted against EYO standardising to the mean age and gender mix in the sample. We estimated the difference in geometric mean NFL for values of EYO between −20 and 10 years, adjusted for age at visit and sex, and tested for when the difference between carriers and non-carriers was statistically significantly different from zero (p < 0.05).

Separately, for 27 participants who became symptomatic (before or during the study), NFL concentration was plotted against actual years to/from onset (AYO), rather than EYO. Non-carriers do not have AYO values, so for comparison, we used their mean serum NFL concentration ± 1.96SD to provide a 95% reference range), calculated on the log scale and back-transformed. For the 27 symptomatic carriers, NFL was modelled against AYO, using linear regression with robust standard errors as above; the quadratic and cubic terms for AYO were not statistically significant so were dropped, with only the linear term for AYO being significant. Non-carriers were not included in the AYO model. The modelled geometric mean longitudinal NFL concentration profile (and its 95% confidence interval) for symptomatic mutation carriers was plotted against AYO, with the same standardisation for age and gender as in the EYO graphs for consistency. In this case for comparison with non-carriers, we used the non-carrier geometric mean serum NFL concentration and its 95% confidence interval.

Separate models compared mean log NFL in PSEN1 versus APP carriers and, in PSEN1 carriers, compared those with mutations pre- versus post-codon 200. These models adjusted for age at visit, sex, and EYO, and utilised robust standard errors. All analyses used Stata v15 (StataCorp, College Station, TX, USA).
Results
Participants’ demographic details and serum NfL values are in Table 1 and Fig. 1a. For mutation carriers, 37 had mutations in PSEN1 and nine in APP (Additional file 1: Table S1).

Estimated differences in NfL concentration between the two groups showed that NfL concentration was significantly increased (\(p = 0.045\)) in mutation carriers compared with non-carriers 15 years prior to expected symptom onset, after adjusting for age at visit and sex, and diverged progressively thereafter (Fig. 1b). Modeling NfL for the 27 mutation carriers with known AYO showed a progressive increase over the disease period that these data cover, consistent with the EYO-based analysis (Fig. 2).

Across all participants, adjusting for age at visit, sex, and EYO, there was no significant difference in NfL values between PSEN1 carriers and APP carriers (\(p = 0.63\)). In PSEN1, there was no significant difference in NfL concentration between individuals with mutations pre and post-codon 200 (\(p = 0.67\)).

Discussion
This study supports the utility of serum NfL as a potential biomarker of early neurodegeneration in presymptomatic AD. We extend previous findings by showing that not only is NfL concentration increased in presymptomatic FAD, but also this increase first occurs more than a decade before the onset of clinical symptoms and continues to rise thereafter.

Serum NfL has been associated with validated cognitive and structural imaging markers of disease severity in AD (Fig. 2) [1, 2, 7], including whole-brain volume, atrophy rates, and the MMSE. However, the initial change in NfL in our study appears to occur before these other measures are first thought to become abnormal [8, 9]. While markers of molecular pathology (i.e. CSF A\(\beta_{1-42}\) and amyloid PET) have been previously shown to change as early or earlier than markers of neurodegeneration [9–11], A\(\beta\) alone is not sufficient to cause symptomatic AD; therefore, downstream markers of neuronal loss are vital in helping identify those who are closest to symptom onset [12].

The comparatively early change in NfL compared to other validated markers of neurodegeneration, combined with the relative accessibility and non-invasiveness of a blood-based measure, suggests the potential utility of NfL as a screening measure in presymptomatic trials, and possibly even in the general population if disease-modifying treatments were to become available. However, our sample is relatively young, and it would therefore be important to assess how serum NfL varies between presymptomatic AD and healthy ageing in older individuals (i.e. the age range more relevant to sporadic AD) before any such more general use could be considered.

In mutation carriers, within-person longitudinal measurement of NfL generally demonstrates progressive increase with increasing follow-up time. There is, however, significant inter- and intra-individual variability, with some people exhibiting large changes over relatively short time intervals. Sample processing is unlikely to account for this variability as subject and QC samples were analysed in a consistent manner and QC CV between plates was less than 5%. NfL is a relatively non-specific marker of neuronal damage, and increases can be seen with neurodegeneration and also with neuroinflammation [1, 4, 13]. Coexistence of these pathological processes in FAD may be partly responsible for fluctuations seen in NfL concentration. Equally there may also

Table 1: Participant demographics and serum NfL concentration. For variables with missing data points, the number of observations is shown underneath the group average value (e.g. \(n = x\)). EYO estimated years to/from onset, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating Scale, SOB sum of boxes

|                        | Non-carriers N = 15 | Presymptomatic N = 25 | Symptomatic N = 21 |
|-------------------------|---------------------|-----------------------|---------------------|
| Gender (female/male)    | 11/4                | 13/12                 | 7/14                |
| Age (mean, SD)          | 39.7 (9.1)          | 36.2 (5.8)            | 47.4 (9.3)          |
| EYO (years) (mean, SD)  | n/a                 | –9.25 (6.21)          | 3.09 (3.53)         |
| MMSE (median, IQR)      | 30 (30–30)          | 30 (29–30)            | 23 (19.5–26.5) (\(n = 20\)) |
| CDR Global (median, IQR)| 0 (0–0)             | 0 (0–0)               | 0.5 (0.5–1.0) (\(n = 18\)) |
| CDR SOB (median, IQR)   | 0 (0–0)             | 0 (0–0)               | 3.25 (1.5–4.5) (\(n = 18\)) |
| Baseline NfL (pg/mL)    | 10.34 (7.62)        | 12.83 (6.71)          | 22.60 (12.28)       |
| (mean, SD)              |                     |                      |                     |
| Annualised rate of change in NfL (pg/mL/years) (mean, SD)* | 0.51 (1.54) (\(n = 9\)) | 0.67 (3.72) (\(n = 17\)) | 3.52 (3.72) (\(n = 5\)) |
Further investigation, and improved understanding, of confounding causes of alterations in NfL concentration is needed before this biomarker can be used in clinical practice.

EYO based on parental age at onset is a relatively reliable proxy measure of proximity to symptom onset [14]. However, EYO carries a degree of error, so using AYO when known may provide additional accuracy. As with the EYO-based model, analysis based on AYO shows progressive increase as individuals approach and then pass expected onset. The consistency between these models confirms that NfL is a marker of presymptomatic neurodegeneration and remains elevated after the onset of symptoms.

PSEN1 carriers have been reported to have more widespread atrophy patterns in the early stages of disease progression than APP carriers [15]. However, after adjusting for age at visit, sex and disease stage (i.e. EYO), we found no difference in NfL concentration between PSEN1 and APP carriers. Also, although PSEN1
mutations located post-codon 200 often have more complex clinical phenotypes than those pre-codon 200, this did not translate to a difference in NFL.

Our study has limitations. The sample size was limited, owing primarily to the relative rarity of FAD mutations, and replication, especially of sub-group analyses, is required in larger cohorts. Given the sample size and the degree of fluctuation in NFL concentrations, it was not possible reliably to model rate of change over time within subjects. Also, due to the reliance on EYO, it is difficult to say with certainty the precise time point that NFL first increases. Further assessment of serum NFL in presymptomatic sporadic AD will also be important.

**Conclusions**

We show that serum NFL is already increasing early in the presymptomatic phase of FAD and rises progressively thereafter. It will be important for the sources of intra-individual variability over time to be understood.
Overall, however, serum NFL is a promising, easily accessible marker of early neurodegeneration in AD.

Additional file

Additional file 1: Table S1. Participants’ family mutations. (DOCX 17 kb)

Abbreviations
AD: Alzheimer’s disease; APP: Amyloid Precursor Protein; AY0: Actual years to onset; CDR: Clinical Dementia Rating Scale; EYO: Estimated years to onset; FAD: Familial Alzheimer's disease; MMSE: Mini Mental State Examination; NFL: Neurofilament light; PSEN1: Presenilin 1; SD: Standard deviation; SOB: Sum of boxes

Funding
PSJW is supported by an MRC Clinical Research Training Fellowship. AOC acknowledges support from the Rosetrees Trust and Alzheimer’s Society. NSR is supported by a University of London Chadburn Lectureship in Medicine. SM acknowledges support from the MRC and the NIHR Queen Square Dementia Biomedical Research Centre. KB receives support from the Torsten Söderberg Foundation at the Swedish Royal Academy of Sciences, the Swedish Research Council, the Brain Foundation Sweden, and the Alzheimer Foundation Sweden. The Dementia Research Centre is an ARLUK Co-ordinating Centre and is grateful for support from the UK Dementia Research Institute, the MRC Dementias Platform UK and the Leonard Wolfson Experimental Neurology Centre. The study was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. HZ is a Wallenberg Academy Fellow and receives support from the European Research Council, the Swedish Research Council, the Brain Foundation Sweden, and the Alzheimer Societies Network. The Dementia Research Centre is an ARUK Co-ordinating Centre and is grateful for support from the UK Dementia Research Institute, UCL Institute of Neurology, Queen Square, Box 16, London WC1N 3BG, UK.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
PSJW was involved in the conceptualization and design of the study, collection, analysis, and interpretation of the data, and drafting/revising of the manuscript. TP led the statistical analysis and interpretation of the data and assisted in the drafting/revising of the manuscript. AO contributed to the collection, analysis, and interpretation of the data and drafting/revising of the manuscript. AH contributed to the analysis of serum samples and drafting/revising of the manuscript. NSR contributed to the collection of the data and drafting/revising of the manuscript. YL contributed to the collection of the data and drafting/revising of the manuscript. RD contributed to the analysis of serum samples and drafting/revising of the manuscript. SM contributed to the analysis of serum samples, interpretation of the data, and drafting/revising of the manuscript. KB contributed to the analysis of serum samples, interpretation of the data, and drafting/revising of the manuscript. JMS contributed to the interpretation of the data and drafting/revising of the manuscript. CF supervised the statistical analysis and interpretation of the data and drafting/revising of the manuscript. HZ contributed to the conceptualization and design of the study, analysis of serum samples and interpretation of results, and drafting/revising of the manuscript. NCF contributed to the conceptualization and design of the study, interpretation of results, and drafting/revising of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Queen Square Research Ethics Committee and all participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
K. Blennow has served as a consultant or at advisory boards for Alzheon, Eli Lilly, Fujirebio Europe, IBL International, Novartis, and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. J. Schott has received research funding from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals and Eli Lilly, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. H. Zetterberg is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, and has served on scientific advisory boards of Roche Diagnostics, Eli Lilly, Sumumed, CogRx, and Wave. N. Fox reports fees (paid to University College London) for consultancy from Janssen, Eli Lilly, Novartis, Sanofi, Roche, and GlaxoSmithKline and for serving on a data monitoring committee for Biogen. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, Queen Square, Box 16, London WC1N 3BG, UK.
2Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
3The UK Dementia Research Institute at UCL and Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
4MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.
5Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Received: 4 November 2018 Accepted: 4 February 2019
Published online: 20 February 2019

References
1. Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89(2):167–75.
2. Sanchez-Valle R, Heslegrave A, Folani MS, Bosch B, Antonell A, Balas M, et al. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):113.
3. Ryan NS, Nicholas JM, Weston PS, Liang Y, Lashley T, Guerreiro R, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer’s disease: a case series. Lancet Neurol. 2016;15(13):1326–35.
4. Rohrer JD, Woollacott IO, Dick KM, Broderick E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329–36.
5. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, vol. 1; 1967. p. 221–33.
6. White HA. Heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817–38.
7. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s disease neuroimaging. Journal of Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557–66.
8. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pellep T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol. 2006;5(10):828–34.
9. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited familial Alzheimer’s disease. N Engl J Med. 2012;366(9):795–804.
10. Benzinger TL, Blazey T, Jack CR Jr, Koepp RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502–9.
11. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvador O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.
12. Jack CR Jr, Themau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol. 2016;15(1):56–64.
13. Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230–7.

14. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253–60.

15. Scahill RI, Ridgway GR, Bartlett JW, Barnes J, Ryan NS, Mead S, et al. Genetic influences on atrophy patterns in familial Alzheimer’s disease: a comparison of APP and PSEN1 mutations. J Alzheimer’s Dis. 2013;33(1):199–212.